Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 4, 2006, Pages 711-716

  Rasiah, Krishan K ^a   Kench, James G ^a,c   Gardiner Garden, Margaret ^a   Biankin, Andrew V ^a   Golovsky, David ^b   Brenner, Phillip C ^b   Kooner, Raji ^b   O'Neill, Gordon F ^b   Turner, Jennifer J ^b   Delprado, Warick ^d   Lee, C Soon ^e,f   Brown, David A ^b   Breit, Samuel N ^b   Grygiel, John J ^b   Horvath, Lisa G ^a,e   Stricker, Phillip D ^b   Sutherland, Robert L ^a   Henshall, Susan M ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d DOUGLASS HANLY MOIR PATHOLOGY   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MACROPHAGE INHIBITORY CYTOKINE 1; NEUROPEPTIDE Y; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CYTOKINES; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEUROPEPTIDE Y; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 33646259501     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0752     Document Type: Article

References (33)

1. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-85.
2. Ashida S, Nakagawa H, Katagiri T, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genomewide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004;64:5963-72.
3. Cheung P, Woolcock B, Adomat H, et al. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 2004;64:5929-33.
4. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci U S A 1997;94:11514-9.
5. Paralkar VM, Vail AL, Grasser WA, et al. Cloning and characterization of a novel member of the transforming growth factor-β/bone morphogenetic protein family. J Biol Chem 1998;273:13760-7.
6. Liu T, Bauskin AR, Zaunders J, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63:5034-40.
7. Albertoni M, Shaw PH, Nozaki M, et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002;21:4212-9.
8. Michel MC, Rascher W. Neuropeptide Y: a possible role in hypertension? J Hypertens 1995;13:385-95.
9. Sheikh SP. Neuropeptide Y and peptide YY: major modulators of gastrointestinal blood flow and function. Am J Physiol 1991;261:G701-15.
10. Pedrazzini T, Seydoux J, Kunstner P, et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 1998;4:722-6.
11. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 1998;75-76:231-8.
12. Kitlinska J, Abe K, Kuo L, et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 2005;65:1719-28.
13. Quinn DI, Henshall SM, Haynes A-M, et al. Prognostic significance of pathological features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-705.
14. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986;17:64-71.
15. Foster C, Bostwick D. Grading prostate cancer. In: Deshmukh N, Foster C, editors. Pathology of the prostate. Philadelphia: WB Saunders; 1998. p. 191-227.
16. Epstein J, Yang X. Grading of prostatic adenocarcinomas, the Gleason system. In: Epstein J, Yang X, editors. Prostate biopsy interpretation. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 154-76.
17. Bostwick DG, Dundore PA. Biopsy pathology of the prostate. 1st ed. London: Chapman and Hall Medical; 1997.
18. Henshall SM, Afar DE, Rasiah KK, et al. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003;22:6005-12.
19. Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642-50.
20. Epstein JI, Grignon DJ, Humphrey PA, et al. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 1995;19:873-86.
21. Bostwick DG, Qian J, Pacelli A, et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 2002;168:1204-11.
22. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 1996;6:3-8.
23. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001;410:940-4.
24. Ekstrand AJ, Cao R, Bjorndahl M, et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A 2003;100:6033-8.
25. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-95.
26. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, ERK1/2, and JNK during the initiation and progression of prostate cancer. Prostate 2003;55:128-39.
27. Welsh JB, Sapinso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-5.
28. Lindmark F, Zheng S, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004;96:1248-54.
29. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2003;2:1023-9.
30. Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localised prostate cancer treated with radical prostatectomy. Cancer Res 2000;60:1585-94.
31. Li PX, Wong J, Ayed A, et al. Placental transforming growth factor-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000;275:20127-35.
32. Rohde M, Dausgaard M, Hartvig Jensen M, Helin K, Nylandsted J, Jaattela M. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 2005;19:570-82.
33. Bauskin AR, Brown D, Junankar S, et al. The propeptide mediates formation of stromal stores of promic-1: role in determining prostate cancer outcome. Cancer Res 2005;65:2330-6.